Todd C. Davis
Todd Davis is a Founding Managing Director at HealthCare Royalty Partners. Mr. Davis has been involved in over $2 billion in healthcare principal investments including sourcing, conducting due diligence, and closing more than $1 billion in royalty financings. Mr. Davis has led, structured, and closed over 40 additional intellectual property licenses, as well as growth equity, and debt deals.
Before co-founding HealthCare Royalty Partners, Mr. Davis was a Partner at Paul Capital Partners, where he co-managed royalty investments as a member of the royalty management committee. Mr. Davis also served as a Partner, responsible for biopharmaceutical growth equity investments at Apax Partners. Prior to beginning his principal investment career in 2001, Mr. Davis held various sales and product management roles at Abbott Laboratories and worked in business development, operations, and licensing at Elan Pharmaceuticals. Mr. Davis has a B.S. from the U.S. Naval Academy and an M.B.A. from Harvard University. Mr. Davis currently serves on the boards of Helomics Corporation, Ligand, and Suneva Medical.
Chief Executive Officer
Preston Romm joined Suneva Medical in June 2016, as its Chief Operating Officer and promoted in August as its Chief Executive Officer. Between 2008 and 2016 Mr. Romm was with Obagi Medical Products, first as its Chief Financial Officer and Executive Vice President of Administration and Operations and then, after the acquisition by Valeant Pharmaceuaticals, as President of Obagi Medical Products and Sr. Vice President of Valeant. Obagi Medical Products is the leader in the physician-dispense skin care market. From 2006 to 2008 Mr. Romm served as Chief Financial Officer for Iomega Corporation, until its sale to EMC Corporation. From 1999 to 2006 Mr. Romm served as the Chief Financial Officer of Dot Hill Systems. Iomega Corporation and Dot Hill Systems were both publicly traded technology companies focused in disk drive storage subsystems.
Between 2004 and 2009 Mr. Romm served on the board of directors of Netlist, Inc. as chairman of the audit committee and member of the nominating and governance committee. He holds a Master of Business Administration in Finance from American University and a Bachelor of Science in Accounting from University of Maryland.
Ron Eastman is a Managing Director at Essex Woodlands in Palo Alto, CA. Having over 35 years of experience in building healthcare businesses, Ron began his career at American Cyanamid Company. There he managed pharmaceutical products, divisions and subsidiaries in the U.S. and overseas, and has since helped build three private healthcare companies—Geron, HCORP, and Rinat Neuroscience.
Under his leadership, Geron became a cutting-edge biotech company growing from a venture-backed startup to a publicly traded pioneer in regenerative medicine and cancer treatment. HCORP established itself as the leader in hospital-based, interactive patient services, and was sold to a diversified competitor. At Rinat, Ron led the effort to build the first company dedicated to discovering and developing large molecule drugs for treating nervous system disorders. Rinat was acquired by Pfizer for $500 million in 2006.
Mr. Eastman serves on the boards of Corium International, EluSys Therapeutics, Inc., IntegenX Inc., Revance Therapeutics, Inc., Suneva and Symphogen.
Brian Chee is a general partner of Polaris Partners, with a primary focus on investments in healthcare and technology companies. Mr. Chee’s vast board experience incorporates currently serving on the boards of Bohola, Data Sciences, Ella Health, Medvantx, and US HealthVest. Mr. Chee received his M.B.A. from the Tuck School of Business at Dartmouth, and his B.S. from the U.S. Military Academy at West Point. Prior to joining Polaris in 1996, Mr. Chee attained significant business operations and leadership expertise with Baxter Healthcare, a global, diversified healthcare company with expertise in medical devices, pharmaceuticals and biotechnology.
A decorated veteran, Mr. Chee served as Captain in the U.S. Army Corps of Engineers during the Gulf War. As platoon leader, Mr. Chee was awarded the Bronze Star and the Army Commendation Medal with Valor for successfully completing missions while encountering enemy fire on the front lines.
Clarke B. Futch, Esq.
Clarke Futch is a Founding Managing Director at HealthCare Royalty Partners. He has been raising and deploying capital in the healthcare royalty market for more than a dozen years. Since 2001, he has been responsible for more than 30 royalty investments representing nearly $2 billion. Over the course of his career, he has raised over $5 billion across five investment funds and executed over 150 transactions including royalty, equity, debt and M&A deals. Before co-founding HealthCare Royalty Partners, Mr. Futch was a partner at Paul Capital Partners, where he co-managed the firm’s royalty investments as a member of the royalty management committee. He previously served as a Founder of the healthcare group at Thomas Weisel Partners, and as a Vice President at Raymond James.
Mr. Futch holds a B.A., magna cum laude, from Vanderbilt University and a J.D. from the University of Virginia School of Law. He currently serves on the boards of Cardiorentis AG, Helomics Corporation and Suneva Medical. Mr. Futch was recently named one of the future leaders in biotech finance by BioWorld, one of the industry’s leading publications.
Peter Barton Hutt
Mr. Hutt is a member of the Institute of Medicine of the National Academy of Sciences, and serves on a wide variety of academic and scientific advisory boards and on the Board of Directors of several companies. In addition, he has represented the national trade associations for the food, prescription drug, nonprescription drug, dietary supplement, and cosmetic industries. While at the FDA he drafted the legislation that became the Medical Device Amendments of 1976, and beginning in 1962 he has participated in the drafting of most of the major legislation amending the Federal Food, Drug, and Cosmetic Act. He has testified before the House and Senate more than 100 times either as a witness or as counsel accompanying a witness.
Mr. Hutt received his B.A., magna cum laude, from Yale University, his LL.B. from Harvard University, and his LL.M. from New York University.
Dan Piacquadio, MD
Dr. Piacquadio is the former President and Chief Executive Officer of Therapeutics, Inc. In 1997, he led the formation of the company, which is dedicated to the field of dermatology and serves the needs of biotechnology, pharmaceutical and investment communities. Previously, Dr. Piacquadio was director of R&D for Oncotherm, a hyperthermia company, and was responsible for regulatory affairs and clinical development. He went on to establish the clinical research program for the Division of Dermatology at the University of California, San Diego and served as director of this facility from 1989 to 1997.
Dr. Piacquadio has been instrumental in the non-clinical and clinical development phases of many soft tissue augmentation products, including Hylaform (Biomatrix). He played a key role in defining regulatory strategy and clinical development of the first laser-based hair removal technology pioneered by Thermolase. As a consultant to the FDA Generic Drug Group, Dr. Piacquadio co-led the development of the current bioequivalency standards for topical steroids.
Dr. Piacquadio has a B.S. in biomedical engineering from Rensselaer Polytechnic Institute and received his medical degree from the University of Pennsylvania. He received his graduate clinical training at Brown University as an intern in internal medicine, and his dermatology training at University of California, San Diego.
Mary J. Szela
Mary Szela is an accomplished pharmaceutical executive with a 25-year history of Senior Leadership roles at Abbott Laboratories. Most recently, Ms. Szela was Senior Vice President at Global Strategic Marketing and Services, Pharmaceutical Products Group. Previously, Ms. Szela served as Senior Vice President at U.S. Pharmaceuticals, an $8 billion dollar U.S. pharmaceutical business. From 2001 to 2008, Ms. Szela directed the development, launch, and growth of more than eight new pharmaceutical products, including leadership of Abbott’s flagship product, Humira.
Prior to 2001, Ms. Szela held a series of leadership positions in Abbott’s Hospital products division where she was responsible for the Peri-operative, Intensive Care, and Pain Management pharmaceutical business, the Global One-2-One outsourcing business, critical care device business, and the vascular medicine pharmaceutical business. She has a B.A. in nursing and a master’s degree in business administration from the University of Illinois.
Dennis Condon is currently a member of the Audit and Risk Committee and the Remuneration and Nomination Committee, as well as CEO and President of Nuvesse Skin Therapies, a venture-backed cosmeceutical skincare company that has launched 12 products into the US medical device market. He was formerly CEO and President of Merz Aesthetics, Inc. (from September 2011 to January 2013), after serving as President and Chief Business Officer from July 2007 and a board member from 2004 to 2007. Additionally, Mr. Condon was the former CEO of BioForm Medical (acquired by Merz Aesthetic for US$250 million).
Mr. Condon carries 30 years of experience in key executive roles in the plastic surgery market, including serving as the President and CEO of Mentor Aesthetics, one of the two largest global breast implant manufacturers.